Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 163 participants.

Also called NCT02624869

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 163 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02624869
  • EudraCT 2015-002276-25
Other papers using this trial's data
  • Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia European journal of preventive cardiology, 2026-07-14 DOI, PubMed 39531353

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, Greece, Hungary, Italy, Malaysia, Netherlands, Norway, Poland, Portugal, Russia, Slovenia, South Africa, Spain, Switzerland, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02624869. Allocation not applicable; no masking; primary purpose treatment. Start 2016-09-10 (actual); primary completion 2021-06-01 (actual). Results posted on 2022-01-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
Acronym
HAUSER-OLE
Intervention (Biological)
Evolocumab
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct02624869
Content hash
06e319e6f8472233e7f466a2dce518c9048f1d53c85f11bfaf8ac8a56df065cc